(NASDAQ: GNLX) Genelux's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.65%.
Genelux's earnings in 2025 is -$31,874,000.On average, 8 Wall Street analysts forecast GNLX's earnings for 2025 to be -$33,066,989, with the lowest GNLX earnings forecast at -$32,442,940, and the highest GNLX earnings forecast at -$33,162,118. On average, 8 Wall Street analysts forecast GNLX's earnings for 2026 to be -$38,036,550, with the lowest GNLX earnings forecast at -$44,003,068, and the highest GNLX earnings forecast at -$32,363,031.
In 2027, GNLX is forecast to generate -$36,742,790 in earnings, with the lowest earnings forecast at -$40,646,902 and the highest earnings forecast at -$32,363,031.